Answers are grounded in this paper and cite their sources.
Substance use disorders (SUDs) impose a substantial public health burden. In addition to behavioral therapies, pharmacological options are available for some SUDs. Repetitive transcranial magnetic stimulation (rTMS) is emerging as a therapeutic modality, but evidence on its benefits and tolerability when combined with pharmacotherapy remains limited. This narrative review examines therapeutic rTMS alongside pharmacotherapy for addictive disorders. MEDLINE, Embase, PsycINFO, PubMed, and CENTRAL were searched from inception to 6 September 2026; PsycArticles, Web of Science, and Scopus were searched on 4 November 2026. Twenty-one studies, including 12 controlled comparisons, were synthesized descriptively. Controlled behavioral benefits were concentrated in tobacco studies; craving and psychiatric outcomes were heterogeneous. Reported adverse effects were generally mild and transient, although safety reporting was incomplete. No study directly compared medication conditions during active rTMS, precluding conclusions about pharmacological synergy or optimal pairings. Integration into addiction services is promising but requires evidence of durable behavioral benefit. rTMS after medical stabilization during the transition from detoxification to rehabilitation, followed by continuing pharmacotherapy, warrants investigation. Future directions include optimizing medication regimens, stimulation protocols, maintenance, and targeting while evaluating substance use outcomes, treatment attendance, and safety to establish which combinations benefit which patients. Medicines help many people with addiction, but some need additional treatment. Repetitive transcranial magnetic stimulation uses magnetic pulses applied outside the head to change brain activity without surgery. We reviewed research on this treatment in people taking medicines for addiction. We searched eight research databases and screened reference lists, identifying 21 studies. Twelve compared people receiving brain stimulation with people not receiving real stimulation. The studies covered tobacco, alcohol, opioids, cocaine, sedatives, gaming disorder, and gambling disorder. Some studies found that adding brain stimulation helped people stop smoking or smoke fewer cigarettes. Results for cravings, meaning strong urges to use a substance or engage in gaming, varied. Reduced cravings did not always accompany reduced substance use. Beyond smoking, some studies found reduced cravings in people with other addictions, but it remains unclear whether these improvements lead to reduced alcohol or drug use. Reported side effects were mostly mild or temporary, particularly headaches. One report described a suspected seizure, but it may not have been caused by repetitive transcranial magnetic stimulation alone. Most studies have small-to-moderate sample sizes and do not always have complete follow-up, which limits conclusions. No study directly tested which medicine works best with stimulation or whether a medicine strengthens its effects. The evidence supports further research, particularly for smoking cessation, but does not establish the best treatment combination. Future studies need to assess lasting changes in substance use, safety, and whether people can complete treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: